Effect of kangai injection combined with platinum-based chemotherapy on the immune function of patients with advanced non-small-cell lung cancer: A meta-analysis

Background: Kangai injection (KAI) is a well-known Chinese patent medicine applied for several different types of cancers in the clinic as an auxiliary therapeutic approach, which is refined from three herbal extracts (Astragalus, Ginseng and Matrine).& nbsp;Purpose: To systematically evaluate the effect of combination treatment of platinum-based chemotherapy and KAI on patients with advanced non-small-cell lung cancer (NSCLC).Study design: A meta-analysis of randomized clinical trials.& nbsp;Materials and methods: The randomized controlled trials (RCTs) about stage III -IV NSCLC using KAI combined platinum-based chemotherapy were electronically retrieved from eight electronic databases up to July 2021. We applied RevMan 5.4, Stata 16.0, TSA 0.9.5.10 Beta and GRADE Pro-GDT to evaluate the quality of the included RCTs and perform the meta-analysis.& nbsp;Results: 19 RCTs were included, consisting a total sample size of 1,389 cases. Meta-analysis revealed that compared with chemotherapy alone, KAI combined with platinum-based chemotherapy was associated with significantly higher objective response rate (ORR) [RR = 1.36, 95%CI (1.21,1.54), p < 0.00001], higher disease control rate (DCR) [RR = 1.15, 95%CI (1.09,1.21), p < 0.00001], greater Karnofsky performance status (KPS) [RR = 1.75, 95%CI (1.41,2.18), p < 0.00001], lower white blood cell toxicity [RR = 0.67, 95%CI (0.55,0.82), p = 0.0001], lower platelet toxicity [RR = 0.60, 95%CI (0.47,0.75), P < 0.0001], and lower incidence of vomiting [RR = 0.66, 95%CI (0.57,0.76), p < 0.00001]. In terms of the immune function, KAI united with chemotherapy significantly raised the ratio of CD3+ cells [MD = 10.65, 95%CI (8.21,13.09), p < 0.00001], CD4+ cells [MD = 7.67, 95%CI (6.31,9.03), p < 0.00001], NK cells [MD = 4.97, 95%CI (3.03,6.92), p < 0.00001], and CD4+/ CD8+ [MD = 0.32, 95%CI (0.19,0.45), p < 0.00001], and decreased the percentage of CD8+ cells [MD =-5.56, 95%CI (-7.51,-3.61), p < 0.00001].& nbsp;Conclusions: This meta-analysis identified that the combination treatment of KAI and platinum-based chemotherapy was more beneficial to patients with advanced NSCLC when compared to chemotherapy alone, which could significantly improve the clinical efficacy, enhance the immune function, and reduce chemotherapy toxicity. Our study provides a theoretical basis and treatment guidance for patients with NSCLC.